Yao Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yao Hu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hui Yu
Department of Infectious Diseases, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, China
3 shared publications Lijing Ye
Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2 shared publicationsShuzhen Han
Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2 shared publicationsXia Wu
Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2 shared publicationsXiaohong Wang
Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2 shared publicationsYingzi Ye
Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2 shared publications
Latest Publications
- Open Access
- 23 August 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 123, 112-118
Liver histology of treatment-naïve children with chronic hepatitis B virus infection in Shanghai China
- 23 August 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 123, 112-118
Open AccessLiver histology of treatment-naïve children with chronic hepatitis B virus infection in Shanghai China
- Open Access
- 7 March 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (4)
Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV
Hepatitis B virus exposure in children usually develops into chronic hepatitis B (CHB). Although hepatitis B surface antigen (HBsAg)–specific CD8+ T cells contribute to resolve HBV infection, they are preferentially undetected in CHB patients. Moreover, the mechanism for this rarely detected HBsAg-specific CD8+ T cells remains unexplored. We herein found that the frequency of HBsAg-specific CD8+ T cells was inversely correlated with expansion of monocytic myeloid-derived suppressor cells (mMDSCs) in young rather than in adult CHB patients, and CCR9 was upregulated by HBsAg on mMDSCs via activation of ERK1/2 and IL-6. Sequentially, the interaction between CCL25 and CCR9 mediated thymic homing of mMDSCs, which caused the cross-presentation, transferring of peripheral HBsAg into the thymic medulla, and then promoted death of HBsAg-specific CD8+ thymocytes. In mice, adoptive transfer of mMDSCs selectively obliterated HBsAg-specific CD8+ T cells and facilitated persistence of HBV in a CCR9-dependent manner. Taken together, our results uncovered a novel mechanism for establishing specific CD8+ tolerance to HBsAg in chronic HBV infection.
- 7 March 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (4)
Open AccessMonocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV
Hepatitis B virus exposure in children usually develops into chronic hepatitis B (CHB). Although hepatitis B surface antigen (HBsAg)–specific CD8+ T cells contribute to resolve HBV infection, they are preferentially undetected in CHB patients. Moreover, the mechanism for this rarely detected HBsAg-specific CD8+ T cells remains unexplored. We herein found that the frequency of HBsAg-specific CD8+ T cells was inversely correlated with expansion of monocytic myeloid-derived suppressor cells (mMDSCs) in young rather than in adult CHB patients, and CCR9 was upregulated by HBsAg on mMDSCs via activation of ERK1/2 and IL-6. Sequentially, the interaction between CCL25 and CCR9 mediated thymic homing of mMDSCs, which caused the cross-presentation, transferring of peripheral HBsAg into the thymic medulla, and then promoted death of HBsAg-specific CD8+ thymocytes. In mice, adoptive transfer of mMDSCs selectively obliterated HBsAg-specific CD8+ T cells and facilitated persistence of HBV in a CCR9-dependent manner. Taken together, our results uncovered a novel mechanism for establishing specific CD8+ tolerance to HBsAg in chronic HBV infection.
- Open Access
- 20 April 2021
- Published by Springer Nature in Research Square
Histology and Clinical Characteristics of Asymptomatic Treatment-naïve Children with Chronic Hepatitis B in Shanghai China
BACKGROUND & AIMS: Chronic hepatitis B (CHB) virus infection is a major cause of morbidity and mortality. We aim to investigate the association between hepatic histology and clinical characteristics in asymptomatic treatment-naïve children chronically infected with hepatitis B virus (HBV) in Shanghai China. METHODS: Liver biopsies of 278 asymptomatic treatment-naïve children with chronic hepatitis B virus infection were scored for inflammation and fibrosis, and correlated with clinical and laboratory data. RESULTS: The clinical, virologic and pathologic features of chronic HBV infection were studied in 278 treatment-naïve children from Shanghai, China, of who were all asymptomatic. And 177 (63.7%) of the children were male. Sera from mothers of 277 of these children were HBsAg positive. Up to 87.4% of subjects were hepatitis B e antigen-positive at the time of the biopsy. The median age at biopsy was 5.1 years (interquartile range 2.8-8.4 years). HBV DNA levels were generally high (mean 7.4 log10 IU/mL), as was serum alanine aminotransferase (median 105 U/L). Using the Ishak-modified histology activity index scoring system, no inflammation was seen in 2.9% cases, mild inflammation was in 22.3%, moderate in 73.4%, and severe in 1.4%. No fibrosis was seen in 11.5%, mild fibrosis in 32.7%, moderate fibrosis in 47.5%, and cirrhosis in 8.3%. When serum ALT level was < 80 (2×ULN) and > 80 U/L, the degree of inflammation (PP3 years (PCONCLUSION: Significantly wide range of inflammation and fibrosis is seen in asymptomatic treatment-naïve children with chronic hepatitis B in Shanghai China. Serum ALT >80 U/L may be a strong indicator of the degree of hepatic inflammation and severity of fibrosis. Moderate fibrosis and cirrhosis has already appeared in aged <3 years children.
- 20 April 2021
- Published by Springer Nature in Research Square
Open AccessHistology and Clinical Characteristics of Asymptomatic Treatment-naïve Children with Chronic Hepatitis B in Shanghai China
BACKGROUND & AIMS: Chronic hepatitis B (CHB) virus infection is a major cause of morbidity and mortality. We aim to investigate the association between hepatic histology and clinical characteristics in asymptomatic treatment-naïve children chronically infected with hepatitis B virus (HBV) in Shanghai China. METHODS: Liver biopsies of 278 asymptomatic treatment-naïve children with chronic hepatitis B virus infection were scored for inflammation and fibrosis, and correlated with clinical and laboratory data. RESULTS: The clinical, virologic and pathologic features of chronic HBV infection were studied in 278 treatment-naïve children from Shanghai, China, of who were all asymptomatic. And 177 (63.7%) of the children were male. Sera from mothers of 277 of these children were HBsAg positive. Up to 87.4% of subjects were hepatitis B e antigen-positive at the time of the biopsy. The median age at biopsy was 5.1 years (interquartile range 2.8-8.4 years). HBV DNA levels were generally high (mean 7.4 log10 IU/mL), as was serum alanine aminotransferase (median 105 U/L). Using the Ishak-modified histology activity index scoring system, no inflammation was seen in 2.9% cases, mild inflammation was in 22.3%, moderate in 73.4%, and severe in 1.4%. No fibrosis was seen in 11.5%, mild fibrosis in 32.7%, moderate fibrosis in 47.5%, and cirrhosis in 8.3%. When serum ALT level was < 80 (2×ULN) and > 80 U/L, the degree of inflammation (PP3 years (PCONCLUSION: Significantly wide range of inflammation and fibrosis is seen in asymptomatic treatment-naïve children with chronic hepatitis B in Shanghai China. Serum ALT >80 U/L may be a strong indicator of the degree of hepatic inflammation and severity of fibrosis. Moderate fibrosis and cirrhosis has already appeared in aged <3 years children.
- 5 September 2019
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 15 (6) , 595-600
Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China
Interferon alpha (IFN-α) is a preferred therapy for antiviral treatment of children with chronic hepatitis B (CHB) aged > 1 year currently. Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years. But the exact efficacy and safety of IFN-α and Peg-IFN α-2a for treating CHB are not sufficient.
- 5 September 2019
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 15 (6) , 595-600
Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China
Interferon alpha (IFN-α) is a preferred therapy for antiviral treatment of children with chronic hepatitis B (CHB) aged > 1 year currently. Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years. But the exact efficacy and safety of IFN-α and Peg-IFN α-2a for treating CHB are not sufficient.